E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast cancer |
|
E.1.1.1 | Medical condition in easily understood language |
pre-treated post-menopausal patients with metastatic breast cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027475 |
E.1.2 | Term | Metastatic breast cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Safety of treatment of the combination of DHEA and an aromatase inhibitor (anastrozole or letrozole or exemestane) in pre-treated post-menopausal metastatic breast cancer patients
• Efficacy (evaluated as clinical benefit) of treatment of the combination of DHEA and an aromatase inhibitor (anastrozole or letrozole or exemestane) in pre-treated post-menopausal metastatic breast cancer patients
|
|
E.2.2 | Secondary objectives of the trial |
• To assess quality of life (QOL) of patients
• To evaluate time-to-event endpoints (TTP, OS, DOR).
For the biological part, we will evaluate:
1) Correlation between AR expression and clinical and biological features
2) Evaluation of AR expression on primitive and/or metastatic site in the two distinct populations of patients: ER/PgR- neg/AR-pos and ER-pos and/or PgR-pos/AR-pos
3) Evaluation of ER, PgR, HER2 expression on tumor cells of metastatic site (when it is possible) and comparison with the same features of primitive tumor.
4) CTCs analysis in term of molecular characteristics (gene expression and mutations) and functionality (vitality and tumorigenicity)
5) Prognostic and predictive role of CTCs evaluated at baseline before study treatment and at the moment of discontinuation of treatment.
6) Measurement of serum glucuronidated DHEA metabolites concentration at baseline before study treatment and at the moment of discontinuation of treatment |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients with metastatic breast cancer
2. AR receptor positivity of primary tumor cells or tumor cells of a metastatic site is required
3. primary tumor cells or tumor cells of a metastatic site imust be HER2 negative
4. Patients must have measurable disease
5. In case of ER-positive disease, previous endocrine treatment in adjuvant or metastatic setting is required and patients must be resistant to aromatase inhibitors. In particular DHEA will be administered in combination with the same aromatase inhibitor during which the progression of disease was found
6. No more than 2 previous lines of chemotherapy for ER-pos tumors and not more than 3 lines of chemotherapy for ER-neg tumors are allowed
7. Women must be in post-menopausal status
8. Life expectancy must be of greater of 12 weeks
|
|
E.4 | Principal exclusion criteria |
1. AR-receptor negativity of primary tumor cells or tumor cells of a metastatic site. AR is reported as negative if less than 10% of cells immunostained in a tumor.
2. HER2 positivity of primary tumor cells or tumor cells of a metastatic site
3. Physician opinion of a too rapid disease progression (like disease widespread in visceral organs like liver or lung in few months) that could suggest the physician a more benefit from chemotherapy treatment even if elegibility criteria for enrollment are satisfied
4. Chemotherapy administration within 3 weeks prior to start of protocol therapy or not recovered from adverse events due to agents administered more than 3 weeks earlier
5. Brain metastasis not treated or in progression requiring treatment (radiotherapy, surgery or high dose steroidal and antiedemigen treatment) in the 2 weeks prior to start of protocol therapy. Patients with brain metastasis as unique site of metastasis are excluded
6. Have received supplement of estrogen or progesterone within 4 weeks prioir to study enter
7. Major surgery during the 21 days before before starting of protocol therapy or planned during the study treatment.
8. Other detectable malignant neoplastic diseases (even a second primitive breast cancer) in the patient’s medical history with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma of the skin and in situ carcinoma of the uterine cervix);
9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
10. Participation in another clinical trial with any investigational agents within 3 weeks prior to study screening.
11. Previous treatment with androgens or DHEA. Previous treatment with AI is required in case of ER+ and/or PgR positive tumors
12. History of allergic reactions attributed to compounds of similar chemical or biologic composition to DHEA or AI
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Safety of treatment of the combination of DHEA and an aromatase inhibitor (anastrozole or letrozole or exemestane) in pre-treated post-menopausal metastatic breast cancer patients
• Efficacy (evaluated as clinical benefit) of treatment of the combination of DHEA and an aromatase inhibitor (anastrozole or letrozole or exemestane) in pre-treated post-menopausal metastatic breast cancer patients
The first 6 enrolled patients will be closely controlled for safety (at day 14 and 28 of the cycle 1 and 2, assessing compliance, tumor and treatment-related signs and symptoms, laboratory exames) and further patients will be enrolled only in absence of severe toxicity resulting in discontinuation during the first 2 months since the beginning of the protocol treatment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• To assess quality of life (QOL) of patients
• To evaluate time-to-event endpoints (TTP, OS, DOR).
For the biological part, we will evaluate:
1) Correlation between AR expression and clinical and biological features (tumor size, nodal status, histotype, grading, proliferative index, ER, PgR, HER2)
2) Evaluation of AR expression on primitive and/or metastatic site in the two distinct populations of patients: ER/PgR- negative/AR-positive and ER-positive and/or PgR-positive/AR-positive
3) Evaluation of ER, PgR, HER2 expression on tumor cells of metastatic site (when it is possible) and comparison with the same features of primitive tumor.
4) CTCs analysis in term of molecular characteristics (gene expression and mutations) and functionality (vitality and tumorigenicity)
5) Prognostic and predictive role of Circulating Tumor Cells (CTC) evaluated at baseline before study treatment and at the moment of discontinuation of treatment.
6) Measurement of serum glucuronidated DHEA metabolites [as androsterone (ADT)-G, 3alpha (α)-diol-G, estrone (E1)-G and estradiol (E2)-G] concentration at baseline before study treatment and at the moment of discontinuation of treatment. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
quality of life and biological analysis
|
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |